What question did this study set out to answer?

This research aims to evaluate the efficacy of mirvetuximab soravtansine and carboplatin in patients with recurrent platinum-sensitive ovarian cancer, particularly focusing on prior PARPi exposure.

July 4, 2026Open Access

107O Mirvetuximab soravtansine (MIRV) plus carboplatin (Carbo) in folate receptor alpha (FRα)- positive platinum-sensitive ovarian cancer (PSOC): Outcomes by prior poly (ADP-ribose) polymerase inhibitor (PARPi)

Key Points

This research aims to evaluate the efficacy of mirvetuximab soravtansine and carboplatin in patients with recurrent platinum-sensitive ovarian cancer, particularly focusing on prior PARPi exposure.
Conducted a phase II single-arm trial (IMGN853-0420) with patients showing FRα ≥25%.
Assessed objective response rate (ORR) and median progression-free survival (PFS).
Analyzed efficacy outcomes based on prior poly (ADP-ribose) polymerase inhibitor exposure.
Observed an ORR of 68% among participants treated with MIRV plus Carbo.
Achieved a median PFS of 11 months in recurrent PSOC.
Noted that prior PARPi exposure may reduce response to subsequent platinum treatment.

Abstract

In the phase II single-arm IMGN853-0420 trial, MIRV plus Carbo therapy in patients (pts) with FRα ≥25% recurrent PSOC demonstrated an objective response rate (ORR) of 68% and median PFS of 11 mo. In recurrent PSOC, prior PARPi exposure appears to diminish response to subsequent platinum-based rechallenge. Here we explored efficacy by prior PARPi subgroups.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper